Dr Philip Lowden

Article

• Chauviac, Francois-Xavier and Bommer, M. and Yan, Jun and Parkin, G. and Daviter, Tina and Lowden, Philip A.S. and Raven, E. L. and Thalassinos, Konstantinos and Keep, Nicholas H. (2012) Crystal structure of reduced MsAcg a putative nitroreductase from Mycobacterium smegmatis, and a close homologue of Mycobacterium tuberculosis Acg. Journal of Biological Chemistry 287, pp. 44372-44383. ISSN 0021-9258.
• Taylor, D.M. and Balabadra, U. and Xiang, Z. and Woodman, B. and Meade, S. and Amore, A. and Maxwell, M.M. and Reeves, S. and Bates, G.P. and Luthi-Carter, R. and Lowden, Philip A.S. and Kazantsev, A.G. (2011) A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of Sirtuin 2 Deacetylase. ACS Chemical Biology 6 (6), pp. 540-546. ISSN 1554-8929.
• Menalled, L.B. and Patry, M. and Ragland, N. and Lowden, Philip A.S. and Goodman, J. and Minnich, J. and Zahasky, B. and Park, L. and Leeds, J. and Howland, D. and Signer, E. and Tobin, A.J. and Brunner, D. (2010) Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 5 (3), ISSN 1932-6203.
• Hockly, E. and Tse, J. and Barker, A.L. and Moolman, D.L. and Beunard, Jean-Luc and Revington, Adrian P. and Holt, K. and Sunshine, S. and Moffitt, H. and Sathasivam, K. and Woodman, B. and Wanker, E.E. and Lowden, Philip A.S. and Bates, G.P. (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiology of Disease 21 (1), pp. 228-236. ISSN 0969-9961.
• Corre, C. and Lowden, Philip (2004) The first biosynthetic studies of the azinomycins: acetate incorporation into azinomycin B. Chemical Communications 8, pp. 990 -991. ISSN 1359-7345.
• Lowden, Philip and Böhm, G.A. and Metcalfe, S. and Staunton, J. and Leadlay, P.F. (2004) New rapamycin derivatives by precursor-directed biosynthesis. ChemBioChem 5 (4), pp. 535-538. ISSN 1439-4227.
• Giles, G.I. and Giles, N.M. and Collins, C.A. and Holt, K. and Fry, F.H. and Lowden, Philip and Gutowski, N.J. and Jacob, C. (2003) Electrochemical, in vitro and cell culture analysis of integrated redox catalysts: implications for cancer therapy. Chemical Communications 16, pp. 2030-2031. ISSN 1359-7345.
• Hockly, E. and Richon, V.M. and Woodman, B. and Smith, D.L. and Zhou, X.B. and Rosa, E. and Sathasivam, K. and Ghazi-Noori, S. and Mahal, A. and Lowden, Philip and Steffan, J.S. and Marsh, J.L. and Thompson, L.M. and Lewis, C.M. and Marks, P.A. and Bates, G.P. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America 100 (4), pp. 2041-2046. ISSN 0027-8424.
• Smith D.L., None and Woodman B., None and Mahal A., None and Sathasivam K., None and Ghazi-Noori S., None and Lowden, Philip and Bates G.P., None and Hockly E., None (2003) Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Annals of Neurology 54 (2), pp. 186-196. ISSN 0364-5134.